OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics reported Q1 2026 revenue of $59.4 million, up 13% year-over-year, driven by 14% growth in Trauma & Deformity and 22% international growth. Adjusted EBITDA swung to a positive $2.2 million compared to a loss of $0.4 million in the prior year, while free cash flow usage improved by 40%.
Key figures
- Revenue
- 59400000
- Guidance
- FY26 revenue $263.0M-$267.0M, raised from $262.0M-$266.0M
- Adjusted ebitda
- 2200000
- Free cash flow improvement
- 40% reduction in usage
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.